Have a feature idea you'd love to see implemented?
Let us know!
LYRA Lyra Therapeutics Inc
Price (delayed)
$0.253
Market cap
$16.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$19.41M
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose
Highlights
Lyra Therapeutics's gross profit has increased by 47% YoY and by 8% from the previous quarter
The company's revenue rose by 47% YoY and by 8% QoQ
LYRA's equity has dropped by 69% year-on-year and by 60% since the previous quarter
Lyra Therapeutics's net income has shrunk by 67% YoY and by 47% QoQ
Key stats
What are the main financial stats of LYRA
Market
Valuations
Earnings
Shares outstanding
65.46M
Market cap
$16.56M
Enterprise value
$19.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
9.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.67
Revenue
$1.82M
EBIT
-$101.33M
EBITDA
-$101.03M
Free cash flow
-$78.88M
Per share
Balance sheet
Liquidity
EPS
-$1.58
Free cash flow per share
-$1.21
Book value per share
$0.51
Revenue per share
$0.03
TBVPS
$1.44
Total assets
$94.58M
Total liabilities
$63.61M
Debt
$36.75M
Equity
$30.98M
Working capital
$50.16M
Debt to equity
1.19
Current ratio
3.6
Quick ratio
3.61
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
-5,551.3%
Gross margin
100%
Net margin
-5,570.9%
Operating margin
-5,813.3%
Return on assets
-81.2%
Return on equity
-143.7%
Return on invested capital
-94.6%
Return on capital employed
-134.6%
Return on sales
-5,567.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYRA stock price
How has the Lyra Therapeutics stock price performed over time
Intraday
-9.64%
1 week
8.68%
1 month
-7.6%
1 year
-92.47%
YTD
-95.17%
QTD
-1.56%
Financial performance
How have Lyra Therapeutics's revenue and profit performed over time
Revenue
$1.82M
Gross profit
$1.82M
Operating income
-$105.8M
Net income
-$101.39M
Gross margin
100%
Net margin
-5,570.9%
Lyra Therapeutics's net income has shrunk by 67% YoY and by 47% QoQ
The company's operating income has shrunk by 66% YoY and by 44% QoQ
Lyra Therapeutics's gross profit has increased by 47% YoY and by 8% from the previous quarter
The company's revenue rose by 47% YoY and by 8% QoQ
Growth
What is Lyra Therapeutics's growth rate over time
Valuation
What is Lyra Therapeutics stock price valuation
P/E
N/A
P/B
0.5
P/S
9.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.67
The EPS is down by 32% since the previous quarter
LYRA's price to book (P/B) is 81% less than its last 4 quarters average of 2.7 and 75% less than its 5-year quarterly average of 2.0
LYRA's equity has dropped by 69% year-on-year and by 60% since the previous quarter
The price to sales (P/S) is 94% lower than the last 4 quarters average of 142.7
The company's revenue rose by 47% YoY and by 8% QoQ
Efficiency
How efficient is Lyra Therapeutics business performance
The return on equity has dropped by 100% year-on-year and by 82% since the previous quarter
The return on assets has dropped by 56% since the previous quarter and by 50% year-on-year
LYRA's return on invested capital is down by 40% since the previous quarter but it is up by 32% year-on-year
The ROS is down by 36% since the previous quarter and by 13% year-on-year
Dividends
What is LYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYRA.
Financial health
How did Lyra Therapeutics financials performed over time
The total assets is 49% greater than the total liabilities
Lyra Therapeutics's total liabilities has surged by 135% YoY
The current ratio has plunged by 57% YoY and by 25% from the previous quarter
The debt is 19% greater than the equity
The company's debt to equity has surged by 143% QoQ
LYRA's equity has dropped by 69% year-on-year and by 60% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.